Dr. Jian Liu 刘健
Chief Physician
Department of Medical Oncology for Breast Cancer, Fujian Cancer Hospital, Fuzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of breast cancer, including chemotherapy, endocrine therapy, biological therapy (molecular targeted therapy and immunotherapy), and comprehensive care.
Dr. Liu graduated from Fujian Medical University in 1984 and serves as Administrative Director of the Department of Medical Breast Oncology at Fujian Cancer Hospital. Dr. Liu holds leadership roles in multiple provincial medical associations and serves on editorial boards for several journals. Research interests include clinical trials for new anti-cancer drugs, with publications in SCI-indexed and provincial journals.
Professional roles
- Vice Chair, Breast Disease Expert Training Committee, Chinese Medical Doctor Association
- Standing Committee Member, Breast Cancer Professional Committee, China Anti-Cancer Association
- Standing Committee Member, Chinese Society of Clinical Oncology (CSCO)
- Member, Breast Group, Chinese Medical Association
Name order: in Chinese the family name comes first (Liu Jian). Papers usually list the name as Jian Liu or Liu J.
Selected publications
32 papers on PubMed matched by name and affiliation; 8 as first or senior author since 2016. Most recent first- or senior-author papers:
- Ther Adv Med Oncol, 2026 (senior author): Real-world outcomes and safety of inetetamab plus pyrotinib and chemotherapy in HER2-positive metastatic breast cancer: A multicenter retrospective study. PubMed 42597517
- BMC Cancer, 2024 (senior author): EZH2 mutation is associated with the development of visceral metastasis by enhancing proliferation and invasion and inhibiting apoptosis in breast cancer cells. PubMed 39300407
- Curr Cancer Drug Targets, 2024 (senior author): The Efficacy and Safety of Inetetamab and Pyrotinib in Combination with Vinorelbine for Second-line Therapy and Beyond in HER2-positive Metastatic Breast Cancer: A Single-institution Clinical Experience. PubMed 37916639
- J Chemother, 2023 (senior author): Tumor mutational burden in non-immunotherapy patients with heavily pretreated metastatic breast cancer: long-term outcomes from a single institution. PubMed 36000459
- Kaohsiung J Med Sci, 2022 (senior author): Corrigendum to "Protective effect of hsa-miR-570-3p targeting CD274 on triple negative breast cancer by blocking PI3K/AKT/mTOR signaling pathway" [Kaohsiung J Med Sci. 2020;36(8):581-591]. PubMed 35286015
- Onco Targets Ther, 2020 (senior author): Pseudoprogression After Palbociclib with Aromatase Inhibitors Treatment in Metastatic Breast Cancer. PubMed 32943874
- Kaohsiung J Med Sci, 2020 (senior author): Protective effect of hsa-miR-570-3p targeting CD274 on triple negative breast cancer by blocking PI3K/AKT/mTOR signaling pathway. PubMed 32311203
- Gynecol Oncol, 2018 (senior author): BRCA germline mutations in an unselected nationwide cohort of Chinese patients with ovarian cancer and healthy controls. PubMed 30078507
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion